- Home
- JAZZ vs OBDC Comparison
JAZZ vs OBDC Comparison
Compare JAZZ & OBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAZZ
- OBDC
- Stock Information
- Founded
- JAZZ 2003
- OBDC 2015
- Country
- JAZZ Ireland
- OBDC United States
- Employees
- JAZZ 2800
- OBDC N/A
- Industry
- JAZZ Biotechnology: Pharmaceutical Preparations
- OBDC Investment Managers
- Sector
- JAZZ Health Care
- OBDC Finance
- Exchange
- JAZZ Nasdaq
- OBDC Nasdaq
- Market Cap
- JAZZ 7.0B
- OBDC 7.5B
- IPO Year
- JAZZ 2007
- OBDC 2019
- Fundamental
- Price
- JAZZ $108.05
- OBDC $14.29
- Analyst Decision
- JAZZ Strong Buy
- OBDC Buy
- Analyst Count
- JAZZ 12
- OBDC 8
- Target Price
- JAZZ $183.00
- OBDC $15.50
- AVG Volume (30 Days)
- JAZZ 628.2K
- OBDC 2.7M
- Earning Date
- JAZZ 08-05-2025
- OBDC 08-06-2025
- Dividend Yield
- JAZZ N/A
- OBDC 11.91%
- EPS Growth
- JAZZ 49.21
- OBDC N/A
- EPS
- JAZZ 7.51
- OBDC 1.57
- Revenue
- JAZZ $4,064,808,000.00
- OBDC $1,661,827,000.00
- Revenue This Year
- JAZZ $6.10
- OBDC $21.06
- Revenue Next Year
- JAZZ $5.07
- OBDC N/A
- P/E Ratio
- JAZZ $15.07
- OBDC $9.02
- Revenue Growth
- JAZZ 5.76
- OBDC 3.60
- 52 Week Low
- JAZZ $95.49
- OBDC $12.11
- 52 Week High
- JAZZ $148.06
- OBDC $15.73
- Technical
- Relative Strength Index (RSI)
- JAZZ 37.52
- OBDC 41.67
- Support Level
- JAZZ $112.17
- OBDC $13.92
- Resistance Level
- JAZZ $117.39
- OBDC $15.01
- Average True Range (ATR)
- JAZZ 2.64
- OBDC 0.21
- MACD
- JAZZ -0.80
- OBDC -0.08
- Stochastic Oscillator
- JAZZ 4.61
- OBDC 29.80
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About OBDC Blue Owl Capital Corporation
Blue Owl Capital Corp is a specialty finance company and business development company (BDC) focused on providing direct lending solutions to U.S. middle-market companies. The company seeks to generate current income and, to a lesser extent, capital appreciation by targeting investment opportunities with favorable risk-adjusted returns, including senior secured, subordinated, or mezzanine loans and equity-related instruments. Its investment strategies are intended to generate favorable returns across credit cycles with an emphasis on preserving capital.